SP100 Antibody, IgG, Serum
Use
Evaluating the risk of primary biliary cholangitis in anti-mitochondrial antibody (AMA) negative patients by identification of Sp100 antibodies. Estimating risk in AMA-positive patients with incomplete feature of disease. Diagnostic support for primary biliary cholangitis in AMA-negative or uncertain cases.
Special Instructions
This test is a first line test when primary biliary cholangitis is strongly suspected. It should be ordered alongside mitochondrial antibodies (AMA) and gp210 antibodies tests.
Limitations
Serologic tests for autoantibodies, including anti-Sp100, should not be relied upon exclusively to determine the etiology or prognosis of patients with primary biliary cholangitis. A negative result for anti-Sp100 antibodies does not exclude a diagnosis of PBC. Results should be used in conjunction with clinical findings and other tests.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 96565-7
- 96565-7
Result Turnaround Time
2-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.4 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Heat-treated specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |